

GSK to Present New Evolutions in Targeted RNA Drug Delivery Systems

SMI Reports: RNA Therapeutics 2017, 22nd & 23rd February, London, United Kingdom

LONDON, ENGLAND, UNITED KINGDOM, November 17, 2016 /EINPresswire.com/ -- SMI Group are thrilled to have Jeffrey Ulmer, Head of Preclinical Research & Development from GSK, present a keynote at [RNA Therapeutics 2017](#) when it returns to Central London next February.

With a focus on mRNA vaccines, the talk will delve further into key topics surrounding immune responses, animal models, platform technology and rapid response to emerging infectious diseases.

In the run-up to his address, Dr Ulmer said:

“RNA therapeutics, including recent exciting advancements

in RNA-based vaccines, have the potential to be game-changing technologies. This conference will bring together thought leaders from across the technology area...”

Now in its 8th year, the RNA event will aim to deliver a scientific toolkit of ideas to implement targeted delivery and mRNA. Attendees will not only learn about new academic research, but will also hear a selection of case studies from big pharma and bio-pharmaceutical companies currently making medical progress through RNA therapeutics.

“

This conference will bring together thought leaders from across the technology area

GSK

Other notable speakers on the [agenda](#) include:

• Nagy Habib, Head of Surgery, Co-Founder, Imperial College

Healthcare NHS Trust, MiNA Therapeutics

- Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
- Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
- John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
- Steve Hood, Director, Bioimaging, GSK
- David Giljohann, CEO, Excicure
- Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
- Amotz Shemi, CEO, Silenseed
- Sanyogitta Puri, Associate Principal Scientist, AstraZeneca

SMi's 8th annual RNA Therapeutics conference will take place on 22nd & 23rd February 2017 at the Copthorne Tara Hotel in Kensington, London, UK.



Further information including a detailed agenda and full speaker line-up is available at www.therapeutics-rna.com

--- end ---

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit <http://www.therapeutics-rna.com> or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
+442078276162
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.